Mesalazine
- Generic Name
- Mesalazine
- Brand Names
- Apriso, Asacol, Canasa, Delzicol, Lialda, Mezavant, Pentasa, Rowasa, Salofalk, Zaldyon
- Drug Type
- Small Molecule
- Chemical Formula
- C7H7NO3
- CAS Number
- 89-57-6
- Unique Ingredient Identifier
- 4Q81I59GXC
- Background
An anti-inflammatory agent, structurally related to the salicylates and non-steroidal anti-inflammatory drugs like acetylsalicylic acid, which is active in inflammatory bowel disease . Although demonstrably effective in treating and maintaining remission for ulcerative colitis, mesalazine has historically faced a number of issues regarding its lack of stabil...
- Indication
适用于溃疡性结肠炎和克罗恩病（Crohn病）。
- Associated Conditions
- Acute Ulcerative Colitis, Crohn's Disease Relapse, Crohn's Ileocolitis, Mild to Moderate Ulcerative Colitis, Proctitis, Proctitis, Ulcerative, Proctosigmoiditis, Ulcerative Colitis in Remission, Mild Ulcerative Colitis, Mild to moderate distal ulcerative colitis, Moderate Ulcerative colitis
- Associated Therapies
- -
Predicting Response to Standardized Pediatric Colitis Therapy
- Conditions
- Interventions
- First Posted Date
- 2012-02-22
- Last Posted Date
- 2019-09-20
- Lead Sponsor
- Connecticut Children's Medical Center
- Target Recruit Count
- 431
- Registration Number
- NCT01536535
- Locations
- 🇺🇸
Children's Hospital of Boston, Boston, Massachusetts, United States
🇺🇸Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee, United States
🇺🇸Emory Children's Center, Atlanta, Georgia, United States
Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA)
- Conditions
- Interventions
- First Posted Date
- 2012-02-14
- Last Posted Date
- 2019-09-06
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 510
- Registration Number
- NCT01532648
- Locations
- 🇷🇺
Santarus Clinical Investigational Site 9005, Moscow, Russian Federation
🇧🇬Santarus Clinical Investigational Site 4003, Pleven, Bulgaria
🇧🇬Santarus Clinical Investigational Site 4001, Sofia, Bulgaria
The Effect of Long-Acting Mesalamine on Post-Infective Irritable Bowel Syndrome- A Pilot Study
- First Posted Date
- 2011-08-09
- Last Posted Date
- 2020-12-31
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 61
- Registration Number
- NCT01412372
- Locations
- 🇺🇸
University of Utah, Salt Lake City, Utah, United States
Efficacy of Mesalamine in Diarrhea-predominant Irritable Bowel Syndrome (dIBS)
- First Posted Date
- 2011-04-01
- Last Posted Date
- 2014-02-12
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 7
- Registration Number
- NCT01327300
- Locations
- 🇺🇸
University of Florida, Gainesville, Florida, United States
Curcumin + Aminosalicylic Acid (5ASA) Versus 5ASA Alone in the Treatment of Mild to Moderate Ulcerative Colitis
- Conditions
- Interventions
- First Posted Date
- 2011-03-22
- Last Posted Date
- 2016-02-12
- Lead Sponsor
- Sheba Medical Center
- Target Recruit Count
- 50
- Registration Number
- NCT01320436
- Locations
- 🇮🇱
Sheba Medical Center, Ramat Gan, Israel
Mesalazine for the Treatment of Diarrhoea-predominant Irritable Bowel Syndrome (IBS-D)
- Conditions
- Interventions
- First Posted Date
- 2011-03-16
- Last Posted Date
- 2014-01-17
- Lead Sponsor
- University of Nottingham
- Target Recruit Count
- 108
- Registration Number
- NCT01316718
- Locations
- 🇬🇧
Queen's Medical Centre, Nottingham, Notts, United Kingdom
Comparative Efficacy and Safety Study in Patients With Ulcerative Colitis in Remission Phase
- First Posted Date
- 2010-12-09
- Last Posted Date
- 2013-04-04
- Lead Sponsor
- Tillotts Pharma AG
- Target Recruit Count
- 251
- Registration Number
- NCT01257399
- Locations
- 🇨🇳
Shanghai Hospital, Shanghai, China
Comparative Efficacy and Safety Study in Patients With Active Ulcerative Colitis
- First Posted Date
- 2010-12-09
- Last Posted Date
- 2013-04-04
- Lead Sponsor
- Tillotts Pharma AG
- Target Recruit Count
- 251
- Registration Number
- NCT01257386
- Locations
- 🇨🇳
Shanghai Hospital, Shanghai, China
Budesonide Versus Mesalazine Versus Placebo in Lymphocytic Colitis
- Conditions
- Interventions
- First Posted Date
- 2010-09-27
- Last Posted Date
- 2017-07-26
- Lead Sponsor
- Dr. Falk Pharma GmbH
- Target Recruit Count
- 57
- Registration Number
- NCT01209208
- Locations
- 🇩🇪
Magen-Darm-Zentrum, IKE - Internistische Kooperation Eppendorf, Hamburg, Germany
Once Versus Twice Daily Mesalamine to Induce Remission in Pediatric Ulcerative Colitis
- First Posted Date
- 2010-09-14
- Last Posted Date
- 2015-12-08
- Lead Sponsor
- Wolfson Medical Center
- Target Recruit Count
- 86
- Registration Number
- NCT01201122
- Locations
- 🇮🇱
Wolfson Medical Center, Holon, Israel
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.